Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide
Viruses, 2019 Identifying drug resistance mutations is important for the clinical use of antivirals and can help define both a drug’s mechanism of action and the mechanistic basis of resistance. Resistance mutations are often identified one-at-a-time by studying
Adam S. Dingens +3 more
doaj +2 more sources
Patient Care and Support Measures Overcome Reluctance to Initiate New Regimen Containing Enfuvirtide [PDF]
Canadian Journal of Infectious Diseases and Medical Microbiology, 2007 Patients can be resistant to initiation of enfuvirtide therapy because of concerns about self-injection and related issues. Because the introduction of a new drug class can substantially enhance the efficacy of an antiretroviral regimen, supporting the ...
Benoit Trottier
doaj +2 more sources
Canadian Consensus Recommendations for the Optimal Use of Enfuvirtide in HIV/AIDS Patients
Canadian Journal of Infectious Diseases and Medical Microbiology, 2006 BACKGROUND AND OBJECTIVES: An eight-member group consisting of Canadian infectious disease and immunology specialists and a family physician with significant experience in HIV management was convened to update existing recommendations, specifically ...
Anita Rachlis +7 more
doaj +2 more sources
HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes. [PDF]
PLoS ONE, 2010 Enfuvirtide and T-1249 are two HIV-1 fusion inhibitor peptides that bind to gp41 and prevent its fusogenic conformation, inhibiting viral entry into host cells.
Pedro M Matos +2 more
doaj +2 more sources
Treatment Strategy: Role of Enfuvirtide in Managing Treatment-Limiting Side Effects [PDF]
Canadian Journal of Infectious Diseases and Medical Microbiology, 2007 Side effects can limit the options available to physicians for the treatment of HIV infection. Management of these side effects is essential, to avoid cessation of treatment.
Christos Tsoukas
doaj +2 more sources
Triple Active Antiretroviral Regimen Including Enfuvirtide Via the Biojector is Effective and Safe
Canadian Journal of Infectious Diseases and Medical Microbiology, 2007 For full HIV virological suppression, three fully active antiretroviral agents are required. New drug classes should be included to ensure that agents are fully active. The addition of enfuvirtide and efavirenz to the present patient’s new antiretroviral
Mona Loutfy, Colin Kovacs
doaj +2 more sources
Investigating the role of a conserved hydrophobic pocket of gp41 in the anti-HIV activity of fusion inhibitors. [PDF]
Protein SciAbstract Membrane fusion between HIV and host cells requires interaction between the N‐terminal and C‐terminal repeat regions (NHR and CHR) of the gp41 envelope subunit. A deep hydrophobic pocket (HP) on the surface of NHR is considered crucial in this interaction.
Polo-Megías D +9 more
europepmc +2 more sources
Contemporary Antiretroviral Therapy Regimens in People With HIV Who Initiated Treatment in the Pre-Antiretroviral Therapy Era. [PDF]
J Med VirolJournal of Medical Virology, Volume 97, Issue 11, November 2025.
Adachi E +4 more
europepmc +2 more sources
The improved efficacy of Sifuvirtide compared with enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance. [PDF]
PLoS ONE, 2017 Most mechanistic studies on human immunodeficiency virus (HIV) peptide fusion inhibitors have focused on the interactions between fusion inhibitors and viral envelope proteins.
Ping Cao +3 more
doaj +1 more source
AIDS Research and Therapy, 2009 Background The selection of agents for any treatment regimen is in part influenced by physician and patient attitudes. This study investigated attitudinal motivators and barriers to the use of self-injectable antiretroviral agents among physicians and ...
Cohen Calvin +12 more
doaj +1 more source